MindLab LLC
MindLab is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutic products for pain management. The company aims to address critical issues such as addiction, tolerance, side effects, and adherence in pain treatment, ensuring that no one suffers from pain without adequate relief.
Industries
N/A
Nr. of Employees
small (1-50)
MindLab LLC
8 West 126th St., New York, NY 10027
Patents
Products
Combination opioid analgesic formulation (morphine sulfate + dextromethorphan + quinidine)
A combination formulation designed to potentiate analgesia at lower opioid doses while reducing measures associated with addiction and tolerance; demonstrated prolonged antinociceptive activity in rodent models.
Combination opioid analgesic formulation (morphine sulfate + dextromethorphan + quinidine)
A combination formulation designed to potentiate analgesia at lower opioid doses while reducing measures associated with addiction and tolerance; demonstrated prolonged antinociceptive activity in rodent models.
Services
Design and execution of formulation optimization and in vivo preclinical efficacy studies for analgesic compounds, including antinociceptive assays.
Clinical protocol design, regulatory pathway planning, and advisory support for analgesic development programs aimed at NDA approval.
Support for patent filing and portfolio management across multiple international jurisdictions for novel therapeutic formulations.
Design and execution of formulation optimization and in vivo preclinical efficacy studies for analgesic compounds, including antinociceptive assays.
Clinical protocol design, regulatory pathway planning, and advisory support for analgesic development programs aimed at NDA approval.
Support for patent filing and portfolio management across multiple international jurisdictions for novel therapeutic formulations.
Expertise Areas
- Formulation development for analgesics
- Preclinical pharmacology and efficacy testing
- Clinical trial design for pain therapeutics
- Regulatory strategy and FDA engagement
Key Technologies
- Combination drug formulation
- Rodent tail‑flick antinociceptive assay
- In vivo preclinical pharmacology
- IND‑enabling toxicology studies